Literature DB >> 33619115

A TNFR2-hnRNPK Axis Promotes Primary Liver Cancer Development via Activation of YAP Signaling in Hepatic Progenitor Cells.

Yan Meng1,2, Qiudong Zhao1, Liwei An3, Shi Jiao4, Rong Li1, Yan Sang1, Jianping Liao1, Pingping Nie4, Fuping Wen4, Junyi Ju3, Zhaocai Zhou5,6, Lixin Wei7.   

Abstract

Most primary liver cancer (PLC) cases progress mainly due to underlying chronic liver inflammation, yet the underlying mechanisms of inflammation-mediated PLC remain unclear. Here we uncover a TNF receptor II (TNFR2)-hnRNPK-YAP signaling axis in hepatic progenitor cells (HPC) essential for PLC development. TNFR2, but not TNF receptor I (TNFR1), was required for TNFα-induced activation of YAP during malignant transformation of HPCs and liver tumorigenesis. Mechanistically, heterogeneous nuclear ribonuclear protein K (hnRNPK) acted downstream of TNFα-TNFR2 signaling to directly interact with and stabilize YAP on target gene promoters genome-wide, therefore coregulating the expression of YAP target genes. Single-cell RNA sequencing confirmed the association of TNFR2-hnRNPK with YAP expression and the pathologic importance of HPC. Accordingly, expressions of TNFR2, hnRNPK, and YAP were all upregulated in PLC tissues and were strongly associated with poor prognosis of PLC including patient survival. Collectively, this study clarifies the differential roles of TNFRs in HPC-mediated tumorigenesis, uncovering a TNFR2-hnRNPK-centered mechanistic link between the TNFα-mediated inflammatory milieu and YAP activation in HPCs during PLC development. SIGNIFICANCE: This work defines how hnRNPK links TNFα signaling and Hippo pathway transcription coactivator YAP in hepatic progenitor cells during primary liver tumorigenesis. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID: 33619115     DOI: 10.1158/0008-5472.CAN-20-3175

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.

Authors:  Hiroyuki Takahashi; Gumpei Yoshimatsu; Denise Louise Faustman
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

2.  Integrated Analysis Reveals the Gut Microbial Metabolite TMAO Promotes Inflammatory Hepatocellular Carcinoma by Upregulating POSTN.

Authors:  Yonglin Wu; Xingyu Rong; Miaomiao Pan; Tongyao Wang; Hao Yang; Xiejiu Chen; Zhenming Xiao; Chao Zhao
Journal:  Front Cell Dev Biol       Date:  2022-05-23

3.  EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription.

Authors:  Xiaoqing Lu; Liwei An; Guangjian Fan; Lijuan Zang; Weiyi Huang; Junjian Li; Jun Liu; Weiyu Ge; Yuwei Huang; Jingxuan Xu; Shaoqian Du; Yuan Cao; Tianhao Zhou; Huijing Yin; Li Yu; Shi Jiao; Hongxia Wang
Journal:  Cell Res       Date:  2022-02-23       Impact factor: 46.297

4.  Construction of Severe Eosinophilic Asthma Related Competing Endogenous RNA Network by Weighted Gene Co-Expression Network Analysis.

Authors:  Haixia Wang; Zeyi Zhang; Yu Ma; Yuanmin Jia; Bin Ma; Junlian Gu; Ou Chen; Shouwei Yue
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

Review 5.  Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy.

Authors:  Juliane Medler; Kirstin Kucka; Harald Wajant
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

Review 6.  Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer.

Authors:  Muchun Li; Xiaozhen Zhang; Xueli Bai; Tingbo Liang
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

7.  Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.

Authors:  Yaobo Yang; Sipan Chen; Zhaoyong Yan; Yang Jiao; Xiang Yan; Yulong Li
Journal:  Comput Math Methods Med       Date:  2022-07-30       Impact factor: 2.809

8.  A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma.

Authors:  Meng Yuan; Koeun Shong; Xiangyu Li; Sajda Ashraf; Mengnan Shi; Woonghee Kim; Jens Nielsen; Hasan Turkez; Saeed Shoaie; Mathias Uhlen; Cheng Zhang; Adil Mardinoglu
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.